# Efficiency of Antagonist Drugs of the Cellular Transcriptomic Signature of Influenza A Virus Infection.

> **NCT03212716** · PHASE2 · TERMINATED · sponsor: **University Hospital, Lille** · enrollment: 85 (actual)

## Conditions studied

- Flu

## Interventions

- **DRUG:** Oseltamivir
- **DRUG:** Diltiazem
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03212716
- **Lead sponsor:** University Hospital, Lille
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-23
- **Primary completion:** 2022-05-04
- **Final completion:** 2022-05-04
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** rate of inclusion and study affected by covid-19 epidemic
- **Last updated:** 2023-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03212716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03212716, "Efficiency of Antagonist Drugs of the Cellular Transcriptomic Signature of Influenza A Virus Infection.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03212716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*